Icell Gene Therapeutics
Clinical trials sponsored by Icell Gene Therapeutics, explained in plain language.
-
Engineered immune cells aim to tame stubborn IBD
Disease control Not yet recruitingThis early-phase study tests a new treatment called ICG318 CAR-T for people with inflammatory bowel disease (IBD) that hasn't improved with standard therapies. The treatment uses a patient's own immune cells, modified in a lab to target and calm the overactive immune response cau…
Phase: PHASE1, PHASE2 • Sponsor: iCell Gene Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Engineered immune cells take aim at Hard-to-Treat lupus
Disease control Not yet recruitingThis early-phase trial tests a new type of cell therapy called BCMA-CD19-IL-15/IL15sushi compound CAR T cells in 20 people with severe lupus that hasn't improved with standard treatments. The therapy aims to reset the immune system by targeting and eliminating faulty immune cells…
Phase: PHASE1, PHASE2 • Sponsor: iCell Gene Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC